Trevena (NASDAQ:TRVN) Now Covered by Analysts at StockNews.com

Research analysts at StockNews.com initiated coverage on shares of Trevena (NASDAQ:TRVN) in a research report issued to clients and investors on Tuesday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright restated a “neutral” rating and set a $5.00 target price on shares of Trevena in a research report on Thursday, November 14th.

Trevena Stock Performance

Shares of TRVN opened at $1.84 on Tuesday. The firm has a market capitalization of $1.59 million, a P/E ratio of -0.04 and a beta of 1.05. Trevena has a 52 week low of $1.13 and a 52 week high of $19.23. The company has a 50-day simple moving average of $1.70 and a 200-day simple moving average of $3.35.

Trevena (NASDAQ:TRVN) last announced its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported ($5.79) earnings per share for the quarter. The business had revenue of $0.28 million during the quarter. As a group, equities analysts forecast that Trevena will post -23.04 earnings per share for the current year.

Trevena Company Profile

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.